Insight
Scope of Estoppel Post-IPR Proceedings Becoming Clearer
by K. Patrick Herman | March.27.2017
This estoppel provision has been the subject of a number of Federal Circuit and district court decisions.
Insight
Post-Grant Proceedings Complicate Pharmaceutical Litigation
April.04.2016
Since the passage of the America Invents Act in 2011, various changes to the patent litigation landscape have occurred.
Insight
1st Circ. Charts Conservative Post-Actavis Course In Loestrin
by Robert Reznick | February.26.2016
Members of Orrick’s Antitrust & Competition team co-authored an article on a recent First Circuit decision concerning "reverse payment" settlements ...
Insight
The Law of Electronic Signatures, 2014-2015 Edition
by Jeremiah Buckley and John Kromer | December.18.2015
The Law of Electronic Signatures and Records is an essential guide to electronic signatures and records laws, including the context in which the laws ...
Insight
Eight Product-Hopping Takeaways from Namenda Ruling
by Robert Reznick | June.11.2015
Orrick attorneys co-authored an article on the Second Circuit's affirmation of a preliminary injunction in New York v. Actavis and what aspects of ...
Insight
Applying 'structured' rule of reason to reverse payments
by Robert Reznick | May.14.2015
Orrick litigators Howard Ullman and Rob Reznick co-authored an article analyzing a much-anticipated decision from the California Supreme Court ...
Insight
IP Partner Discusses FDA Crackdown of Online Pharmacies
June.28.2013
This article about the Food and Drug Administration’s decision to take action against thousands of websites that sell unapproved prescription ...
Insight
Intellectual Property Partner Quoted on U.S. Supreme Court Ruling
June.17.2013
This article, about the U.S. Supreme Court's ruling that brand-name drugmakers can be sued for paying generic-drug manufacturers to delay the release ...
Insight
IP Partner Quoted on Therasense Patent Case
March.29.2012
This article, about medical technology company Becton Dickson's patent victory against Therasense, quotes New York intellectual property partner ...
Insight
Pharmaceutical Law & Industry Report
by Robert Reznick | July.22.2011
New Regulatory Actions Underscore Global Antitrust/Competition Risk of Altering Product Offerings in Light of Imminent Generic Competition
Insight
Law360: Clarifying Obligation To Report Drug Patent Agreements
by Robert Reznick | June.07.2011
Law360, New York (June 07, 2011, 12:12 PM ET) -- On May 9, 2011, the Federal Trade Commission's Bureau of Competition notified Sanofi-Aventis U.S. ...